skip to Main Content

Canadian biotech sector makes strong showing at BIO2013

Every six weeks, MaRS Innovation’s marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI’s activities or one of our start-up companies. You can read the original post on the MaRS blog.

Downtown Chicago skyline in late April
Chicago‘s famous downtown skyline during the 2013 BIO Convention.

Nearly 14,000 delegates—representing over 1,100 biotechnology companies, academic institutions, state biotechnology centres and related organizations across the United States and more than 60 countries—attended the 2013 BIO International Convention from April 22 to 26, 2013.

The event drew biotechnologists, pharmaceutical industry executives and life sciences researchers, along with sector-based organizations and associations, to Chicago.

According to a press release issued by the conference organizers, BIO 2013 offered “a record number of partnering meetings and panel sessions on the latest science, policy issues and business opportunities and challenges facing the biotechnology industry.”

Continue Reading

Raphael Hofstein gives guest lecture on biotechnology commercialization at Stanford

Raphael Hofstein
Raphael Hofstein, president and CEO of MaRS Innovation

Dr. Raphael Hofstein, president and CEO of MaRS Innovation, delivered a guest lecture on February 1,2013 at the Revitalizing Medical BioTechnology Commercialization symposium, hosted by Stanford University‘s NIH Graduate Training Program in Biotechnology.

The one-day event brought academic, venture capital and industry thought leaders together to reflect on the challenges facing technology transfer processes across the biotech industry.

Continue Reading

CML HealthCare Inc. and MaRS Innovation Enter into Strategic Partnership

CML Healthcare logoMISSISSAUGA, Ontario, September 18, 2012 – CML HealthCare Inc. (TSX: CLC) (the “Company” or “CML”) and MaRS Innovation (MI), a Centre of Excellence for Commercialization and Research, have entered into a strategic partnership to commercialize early-stage technologies that present innovative methods in medical diagnostics.

This story was covered in the Globe and Mail, Canadian Business, 680 News, Reuters, Sympatico.ca, the Huffington Post Canada, Technology Trasnfer Tactics, and the Winnipeg Free Press, among others. It was  distributed via Yahoo! Finance, Healthcare Global.com, marketwire and Digital Journal.

Continue Reading

MaRS Innovation and GlaxoSmithKline Announce Strategic Partnership to Accelerate Translational Research in Health Sciences

TORONTO (May 31, 2011) — MaRS Innovation (MI) and GlaxoSmithKline Inc. (GSK) today announced a new development fund — the GSK-MaRS Innovation Fund — that will support and fast-track the commercialization of some of the country’s most promising translational research coming from 16 leading academic health sciences centres, hospitals and universities derived from MI’s member institutions.

Raphael Hofstein
Raphael Hofstein, president and CEO of MaRS Innovation.

“From the discovery of insulin in 1922 to the discovery of stem cells, Ontario has a rich, proud history of world-class medical and scientific breakthroughs,” said Raphael Hofstein, president and CEO of MaRS Innovation. “Our partnership with GSK Canada furthers Ontario’s position as a major international research hub by providing much needed capital to fund exciting drug discovery and development technologies and bridging the gap to successful commercialization.

“Launching this development fund is also part of a global trend where government, researchers and industry are partnering at the early stage of translational research with an eye to achieving global impact and improving patient care,” Hofstein added.

Continue Reading
Back To Top